9 results about "Syk" patented technology

Provided herein are methods to treat neurodegenerative disease.

Provided are methods for determining if an individual is likely to experience immune-related adverse events (irAEs) if treated for melanoma with a combination of immune checkpoint inhibitors that are an anti-Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) antibody and an anti-programmed death-ligand 1 (PD-1) antibody. The methods include determining differential gene signatures as between individuals who had melanoma and were treated with a combination of a CTLA-4 antibody and an PD-1 antibody but did not experience severe irAEs after the treatment, with the gene signature for an individual who has melanoma but was not treated with an immune checkpoint inhibitor.

Methods for treating leukemia are disclosed based on detecting specific cell states and transcriptional programs within leukemic cells. This disclosure presents a novel therapeutic method for treating acute lymphoblastic leukemia (ALL), including BCR-ABL positive and BCR-ABL1-like ALL subtypes. The method involves detecting specific cell states and transcriptional programs in patient samples and administering targeted therapies based on these characteristics. For a pre-B cell-like state or pre-BCR signaling program, a combination of tyrosine kinase inhibitor (TKI) and SYK inhibitor is used. Conversely, a progenitor-like state or stress-autophagy program is treated with a TKI and a p38 MAPK inhibitor. This approach aims to improve treatment efficacy by tailoring therapy to the leukemia's unique molecular and cellular features, particularly in relapsed cases or when minimal residual disease is present.

The invention relates to application of a compound 101-mer in preparation of an influenza vaccine adjuvant and an influenza vaccine, and belongs to the technical field of biology. The compound 101-mer is used as an influenza vaccine adjuvant for preparing an influenza vaccine, the immune protection effect of the influenza vaccine can be improved, the specific total IgG antibody titer of an influenza antigen and IgG1, IgG2a, IgG2b and IgG3 subtype antibody levels are improved, complete protection is provided after challenge, tissue damage is relieved, and the antiviral activity is remarkably superior to that of compounds 18-mer, 19-mer, 27-mer and LPS; as an adjuvant, the compound 101-mer does not have observable toxicity, can still be well tolerated under a high dosage, and has relatively high safety, and the safety of the compound 101-mer is remarkably superior to that of LPS (Lipopolysaccharide); the action mechanism is clear, and the compound can be used as a Dectin-2 agonist to activate a host immune system through a Syk / NF-kappa B signal channel.

Provided are a salt form and a crystal form of a pyrazole substituted imidazo[1,2-a]quinoxaline derivative, and a preparation method therefor. Specifically disclosed are a salt form and a crystal form of a compound of formula (I), and a preparation method therefor and the use thereof in the preparation of drugs related to dual inhibitors of spleen tyrosine kinase (Syk) and vascular endothelial growth factor 2 (VEGFR2).

The present invention provides compounds of Formula (I) which can be used as Syk inhibitors and potently as therapeutic agents against diseases mediated by Syk.

This invention belongs to the field of pharmaceutical synthesis technology, specifically relating to a compound containing an imidazo[1,2-a]pyrazine fragment, its preparation method, and its applications. The compound containing the imidazo[1,2-a]pyrazine fragment of this invention exhibits significant inhibitory activity against SYK, and also significantly inhibits the proliferation of tumor cells, particularly breast cancer cells, ovarian cancer cells, and liver cancer cells. Furthermore, it can induce apoptosis in ovarian cancer cells, thus providing a novel option for SYK inhibitors used in the treatment of solid tumors.

The invention relates to the use of AT7867, MC1568, ACY-1215, AZD-4547, NPK76- II-72-1, tivozanib, SAR-245409, HG-9-91-01, BIX-01294, UNC-669, WZ-7043, dacomitinib, CC-401, UNC-0638, epigallocatechin gallate (-), SB-239063, GDC-0879, KIN001-260, quizartinib, CGK-733, UNC-1215, XMD11-85H, garcinol, PF-573228, veliparib, VE-821, NVP-TAE684, GSK-J2, masitinib, KU-55933, KIN001-127, KIN001- 270, vandetanib, CG-930, GNF-2, decitabine, SGI-1776, amuvatinib, BS-181, CTB, MGCD-265, olaparib, ZM-447439, AGK-2, bosutinib, JNJ-38877605, RG-108, SYK- inhibitor, AZ-20, and OSI-930 drugs, which aim to suppress immune system escape mechanisms in cancer treatment and reduce the proliferation and survival abilities of cancer cells by interacting with proteins involved in immune escape processes and / or neighbouring proteins of these proteins, in T-cell-based immunotherapies.

The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. Compounds of the disclosure have activity as dual modulators of Janus kinase (JAK), alone, or in combination with one or more of an additional mechanism, including a tyrosine kinase, such as TrkA or Syk, and PDE4, and are useful in the in the treatment or control of inflammation, auto-immune diseases, cancer, and other disorders and indications where modulation of JAK would be desirable. Also described herein are methods of treating inflammation, auto-immune diseases, cancer, and other conditions susceptible to inhibition of JAK and PDE4 by administering a compound herein described.